


**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

Claims 1-73 (cancelled)

Claim 74 (currently amended): A peptidomimetic of the formula:




wherein


$X_1$  is  $(CH_2)_m$ ;

$X_2$  bearing the  $R_5$  substituent is N and all other  $X_2$  are  $CH_2$ ;

$R_5$  is



$R_6$  is  $-(CH_2)_4NH_2$ ,  $-(CH_2)_3NHC(NH_2)=NH$ ,  $-(CH_2)_3NHCOCH_3$ ,  $-(CH_2)_3NHCOOCH_3$ ,  
 $-(CH_2)_2NHC(NH_2)=NH$ ,  $-(CH_2)_2NHCONH_2$ ,  $-(CH_2)_4NHCOH$ ,  $-(CH_2)_4NHCOCH_3$ ,  
 $-(CH_2)_3NHCONHCH_3$ ,  $-(CH_2)_3NHOSO_2NH_2$ ,  $-(CH_2)_3NHOSO_2CH_3$ ,  $-(CH_2)_3NH_2$ ,  
 $-(CH_2)_2CONH_2$ ,  $-(CH_2)_3NH(C=NH)NHMe$ ,  $-(CH_2)_3NH(C=NH)NHEt$ ,  
 $-(CH_2)_3NH(C=NH)NHPr$ ,  $-(CH_2)_3NH(C=NH)NHPr-i$ ,  $-(CH_2)_3NH(C=NH)NH_2$ ,  
 $-(CH_2)_4NHCONH_2$ ,  $-(CH_2)_4NH(C=NH)NH_2$ ,



**R<sub>7</sub>** is R<sub>9</sub>-R<sub>8</sub>, where:

**R<sub>8</sub>** is an L- or D-configuration of Phe, Phe(2-Cl), Phe(4-Cl), Phe(2,4-diCl), Phe(3,4-diCl), Phe(4-NO<sub>2</sub>), Phe(4-Me), Phe(4-Phenyl), HPhc, ~~Phe~~Phg, Trp, Nal 1, Nal 2, Bip, Dip, Bpa, Ser(Bzl), Lys(Z), Lys(Z-2'Br), Lys(Bz), Thr(Bzl), Cys(Bzl), Tyr(BzlCl<sub>2</sub>), pF-Phe, Phe(4-Br), Phe(4-CF<sub>3</sub>), Phe(3,4-diF), Phe(4-I) or Phe(3,4-di-OMe); and

**R<sub>9</sub>** is optionally not present or is an L- or D-configuration of His, Ser(Bzl), Tic, heptanoyl-Ser(Bzl), hexanoyl-Ser(Bzl), Hyp(Bzl), 4-phenylPro, 5-phenylPro, Tiq, Ate, Igl, Hyp(O-2-Naphthyl), Hyp(O-Phenyl), 2-Aic, Idc, 1-Aic, NH<sub>2</sub>(CH<sub>2</sub>)<sub>6</sub>CO-, Benzyl, Beta-homoSer(Bzl), Ser(O-2-Naphthyl), Ser(O-Phenyl), Ser(O-4-Cl-Phenyl).

Ser(O-2-Cl-Phenyl), Thr(Bzl), Tic, heptanoyl-Thr(Bzl), hexanoyl-Thr(Bzl),  
Beta-homoThr(Bzl), Thr(O-2-Naphthyl), Thr(O-Phenyl), Thr(O-4-Cl-Phenyl) or  
Thr(O-2-Cl-Phenyl); and

**n** is 1; and

**m** is 1.

Claims 75-77 (cancelled)

Claim 78 (currently amended): A pharmaceutical composition comprising ~~a~~the peptidomimetic of claim 74 and a pharmaceutically acceptable carrier.

Claim 79 (withdrawn and currently amended): A method of treating a disease or condition comprising administering ~~a~~the peptidomimetic of claim 74 to a mammal in need thereof, wherein the disease or condition is an eating disorder, pathologic obesity, or sexual dysfunction.

Claim 80 (withdrawn): The method of claim 79, wherein the sexual dysfunction is male erectile dysfunction or female sexual dysfunction.

Claim 81 (withdrawn): The method of claim 79, wherein the peptidomimetic is administered as a pharmaceutical composition together with a pharmaceutically acceptable carrier.